ICYMI! Learn from our team about Synlogic's late-stage programs in rare metabolic diseases, and exciting upcoming milestones for our Ph 3 program in PKU: loom.ly/7e9iufQ Thank you Sidoti & Company, LLC! #sidoti $SYBX #SYBX #biotechstocks #growthstocks #valuestocks

SynPheny-3 Clinical Trial is actively recruiting participants living with #PKU. We've made participation flexible with a fully virtual option, so you can participate from almost anywhere in the US! Learn more and sign up today. #PKU #ClinicalTrial #SynPheny3

Synpheny-3 clinical trial is open in the US! In this video, Synlogic team members answer FAQs we've received about the ongoing Synpheny-3 clinical trial. Learn more: loom.ly/m9Fq1Bk

The #PKU Synpheny-3 Clinical Trial is now available in Palo Alto, CA! Virtual, hybrid, and in-person options for participation may be available. To learn more and to speak to our Synlogic clinical trial case manager, visit pkuresearchstudy.com!

Get the latest on Synlogic's important work in rare metabolic diseases, and exciting upcoming milestones for our Ph 3 program in PKU. Watch here: loom.ly/7e9iufQ Thank you Sidoti & Company, LLC! #sidoti $SYBX #SYBX #biotechstocks #growthstocks #valuestocks

The #PKU Synpheny-3 Clinical Trial is now available in Aurora, CO! Virtual, hybrid, and in-person options for participation are available. Scan the QR code to learn more and to speak to Synlogic's clinical trial case manager. #CUAnschutz #CUMedicine CU Anschutz Medical Campus @CUMedicine

Learn about our ongoing, pivotal study in #PKU in this brief (~2 min) video: loom.ly/1Uzqggk or visit pkuresearchstudy.com #phenylketonuria #rarediseases #biotechstocks $SYBX

Curious about PKU, and why Phe lowering is so important in this rare metabolic disease? In this brief clip (2 mins), Dr. Hope Northrup, medical geneticist and expert in #inbornerrors, explains: loom.ly/g1mNb3A #SYBX $SYBX #rarediseases #drugdevelopment

Ramp up on SYBX and our upcoming milestones! Last week's webcast can be seen here: loom.ly/7e9iufQ Thank you Sidoti & Company, LLC! #sidoti $SYBX #SYBX #biotechstocks #investmentideas #growthstocks #valuestocks

The #PKU Synpheny-3 Clinical Trial is now available in Charleston, SC! Virtual, hybrid, and in-person options for participation are also available. Scan the QR code to learn more and to speak to Synlogic's clinical trial case manager.

Among 2023's wins: our IP team's securing protection for the innovations behind SYNB1934 (a.k.a. labafenogene marselecobac). Read up on our accomplishments and upcoming milestones: loom.ly/r2HF30k #biotechinnovation $SYBX #SYBX #biotechstocks #investmentideas

The #PKU Synpheny-3 Clinical Trial is now available in Gainesville, FL! Virtual, hybrid, and in-person options for participation are available. Scan the QR code to learn more and to speak to Synlogic's clinical trial case manager.

3 major milestones in the next 18 months for our #Phase3 study in PKU. Learn more here: loom.ly/zN5Vods $SYBX #SYBX #biotechstocks #investmentideas #catalysts #raredisase

A reminder to those affected by #PKU! #phenylketonuria

Learn about Synlogic's focus on rare metabolic diseases, and our lead asset, SYNB934, now in Phase 3 with a milestone-rich year ahead, in this recent webcast: loom.ly/7e9iufQ Thank you Sidoti & Company, LLC! #sidoti $SYBX #SYBX #biotechstocks $XBI

Last year, SYNB1934 received the FDA's Rare Pediatric Disease, Fast Track, and Orphan Drug designations, Orphan designation from the EMA, AND the WHO's go-ahead for the non-proprietary name: labafenogene marselecobac! Learn more: loom.ly/r2HF30k

Congrats authors! Proud of this manuscript on the journey of SYNB1353, our drug candidate for classical #HCU, published in Cell Host & Microbe: :loom.ly/dU6m0Mg Cell Press #inbornerrors #homocystinuria #rarediseases #synbio #syntheticbiology

The #PKU Synpheny-3 Clinical Trial is now available in Chicago, IL! Virtual, hybrid, and in-person options for participation are available. Scan the QR code to learn more!

The #PKU Synpheny-3 Clinical Trial is now available in Nashville, TN! Virtual, hybrid, and in-person options for participation are available. Scan the QR code or visit pkuresearchstudy.com to learn more.

Last week, we announced the end of our PKU study, Synpheny-3, and that Synlogic will cease operations. Our sincere thanks to all who worked with us, and especially to the PKU & HCU communities, who inspired us and enabled our pursuit of new medicines. loom.ly/FZtxgso